Surgery Partners Inc

SGRY remains in a Stage 2 advancing phase with a robust higher-high/higher-low structure and key support at rising EMAs and the 50 DMA. Despite recent exhaustion signals and an extreme overbought reading, medium-term directional asymmetry favors the upside, but short-term timing is neutral. The optimal approach is to stalk pullbacks into the rising 9/21 EMA and 50 DMA area before initiating long positions.

• ↑Strong analyst revisions (score high) underpin confidence in 2026 targets.
• ↑14.6% YoY growth in total joint surgeries; robotics investments fueling momentum.
• ↓Elevated leverage raises debt-servicing and refinancing concerns.